Drug Trial Radar · NCT05001269
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Feb 22, 2022
Primary completion
Feb 5, 2025
Study completion Feb 5, 2025
Sponsor
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyIndustry
- Sponsor type
- Industry
- First posted
- Aug 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
Conditions
- Primary Hyperoxaluria
- Primary Hyperoxaluria Type 1
- Primary Hyperoxaluria Type 2
- Primary Hyperoxaluria Type 3
Interventions
nedosiranDrug
Monthly subcutaneous dosing throughout study period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Month 6 in Spot Urinary Oxalate-to-creatinine Ratio in PH1, PH2, or PH3 Participant SubgroupsTime frame: Baseline (Week 0), Month 6
- Absolute Change From Baseline to Month 6 in Spot Urinary Oxalate-to-creatinine Ratio in PH1, PH2, or PH3 Participant SubgroupsTime frame: Baseline (Week 0), Month 6
Locations
13 sites in 11 countries. Site status is shown where the registry gives one.
Clinical Research Site
Rochester, Minnesota
Clinical Research Site
Hamilton, Ontario, Canada
Clinical Trial Site
Bonn, Germany
Clinical Research Site
Heidelberg, Germany
Clinical Trial Site
Roma, Italy
Clinical Research Site
Fukuoka, Japan
Clinical Research Site
Nagoya, Japan
Clinical Research Site
Beirut, Lebanon
Clinical Research Site
Bialystok, Poland
Clinical Research Site
Barcelona, Spain
Clinical Research Site
Yenimahalle, Ankara, Turkey (Türkiye)
Clinical Trial Site
Dubai, United Arab Emirates
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.